Research: CLERICI and co-workers,

Listed in Issue 106

Abstract

CLERICI and co-workers, Clinic of Gastroenterology and Hepatology, University of Perugia, Italy, clerici@unipg.it, have tested the treatment of liver cancer with all-trans-retinoic acid plus tamoxifen and vitamin E.

Background

Low serum retinol and vitamin E levels are associated with the risk of hepatocellular carcinoma. In addition, it has been found that the antioestrogen drug, tamoxifen, seems to benefit these patients. This study was aimed to assess a combination therapy with these drugs.

Methodology

15 patients with advanced liver carcinoma were treated with a combination if retinoic acid, vitamin E and tamoxifen. They were evaluated for survival time, quality of life, liver function, tumour mass, toxicity related to the treatment and retinoid receptors in liver biopsies.

Results

The median survival time of these patients was 22 months. Pain and asthenia were improved by the treatment in the majority of patients. All patients showed an improvement in liver function. Retinoid receptors in the liver were increased.

Conclusion

A combination therapy with all-trans retinoic acid, tamoxifen and vitamin E increases the survival rate and ameliorates clinical outcomes in patients with inoperable hepatocellular carcinoma.

References

Clerici C, Castellano D, Russo G, Fiorucci S, Sabatino G, Giuliano V, Gentili G, Morelli O, Raffo P, Baldoni M, Morelli A, Toma S. Treatment with all-trans retinoic acid plus tamoxifen and vitamin E in advanced hepatocellular carcinoma. Anticancer Research 24 (2C): 1255-1260, Mar-Apr 2004.

ICAN 2024 Skyscraper

Scientific and Medical Network 2

Cycle Around the World for Charity 2023

Climb Mount Kilimanjaro Charity 2023

top of the page